Adamis Pharmaceuticl is FAIRLY VALUED at 1.00 per share with modest projections ahead.
We provide trade advice to complement the prevailing
expert consensus on Adamis Pharmaceuticl. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of Adamis Pharma? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with Adamis Pharma this year
Annual and quarterly reports issued by Adamis Pharma are formal
financial statements that are published yearly and quarterly and sent to Adamis stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Adamis Pharma often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Is Adamis a risky opportunity?
Let's check the volatility. Adamis is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Adamis (NASDAQ:ADMP) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. obtaining a share of an Adamis Pharmaceuticl stock makes you a part-owner of that company.
Adamis Pharmaceuticl Current Consensus
Here is the recent trade recommendation based on an ongoing consensus estimate among financial analysis covering Adamis Pharmaceuticl. The Adamis consensus assessment is calculated by taking the average estimates from all of the analysts covering Adamis Pharmaceuticl
| Strong Buy | 0 | 0.0 |
| Buy | 0 | 0.0 |
| Hold | 2 | 100.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Will Adamis pull back in November 2021?
Recent Risk Adjusted Performance is up to -0.04. Price may decline again.
As of the 10th of October, Adamis Pharmaceuticl shows the
mean deviation of 2.85, and Risk Adjusted Performance of
(0.037946). Adamis Pharmaceuticl
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We have collected data for nineteen
technical drivers for Adamis Pharmaceuticl, which can be compared to its rivals. Please confirm
Adamis Pharmaceuticl coefficient of variation, as well as the
relationship between the treynor ratio and
semi variance to decide if Adamis Pharmaceuticl is priced correctly, providing market reflects its regular price of 1.03 per share. Given that Adamis Pharmaceuticl is a hitting penny stock territory we recommend to closely look at its
total risk alpha.
Our Conclusion on Adamis Pharmaceuticl
Although some firms within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Adamis Pharmaceuticl may offer a potential longer-term growth to insiders. With a somewhat neutral outlook on your 90 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Adamis nor trade your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Adamis Pharmaceuticl.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Adamis Pharma. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
